The AI tools you use every day — Claude, ChatGPT, Gemini — are, in a meaningful sense, frozen in time. They learned everything they know during a multi-month training run, and then the learning stopped. New research published in 2025 and 2026 is attacking this problem from five different angles simultaneously. Here’s what’s actually working,…
SciPy 1.0 was published in February 2020. In the twelve months ending October 2025 it was cited 1,731 times. That is a five-year-old methods paper picking up roughly five new citations per day, with the rate still climbing. Its acceleration over the prior year is +94 per month, the third highest in the entire top-300…
Most “trending papers” lists are annual cuts: how many times a paper got cited this year versus last. That misses the shape of the curve. A paper that quietly clocked 200 citations evenly across twelve months looks identical to one that went from 5 per month to 40 per month. The second is actually taking…
In 2023 the European Society of Cardiology published its first comprehensive guideline on cardiomyopathies. OpenAlex has already logged more than 2,100 citations to that single document, a pace that puts it among the fastest-accelerating clinical papers of 2024. The guideline itself is not the story. The story is what it quietly codified: a drug class…
Steven Pinker’s Enlightenment Now proves that, on a 200-year baseline, almost everything is up and to the right. Peter Thiel’s The End of the Future argues that, since 1973, almost nothing in the physical world is. Both can be true. The trick is to plot each metric on its own longest available baseline and see…
Peter Thiel said in 2011 that the future had stalled. Ray Kurzweil said in 2005 that the future was on schedule. Reading both texts now, with a 9.3-million-patent corpus running underneath them, the answer is that they were arguing about different decades — and that the inflection between those decades happened, with disconcerting precision, the…
What started as a search for hidden innovation in medical devices turned into something bigger — a vision for how AI-driven R&D will need to coordinate across fields, and the infrastructure that doesn’t exist yet.
One rabbit-gut bacterium, 130 US patents, and a product ladder that climbs from steel-mill smoke to jet fuel, PET plastic, and Gucci perfume. The company is LanzaTech, its cash is nearly gone, and its patent machine just hit record output.
The eVTOL startups raised $15 billion and got the headlines. GE, Rolls-Royce, Pratt, and Safran hold three times as many US electric-propulsion patents, and every one of them keeps a turbine burning.
Humira soaks up TNF with an injected antibody. In August 2025 the FDA approved a one-minute-a-day nerve implant that hits the same molecule by flipping an immune reflex the body has had all along.
Histotripsy grants tripled to 12 in 2025, and Michigan plus its $2.25B spinout HistoSonics hold 83% of them. The mechanism is now migrating from liver tumors to the immune system.
Whey and egg white fell years ago. Casein, the self-assembling micelle that makes cheese stretch and melt, is the hard one, and three US startups now hold 19 granted patents on building it without a cow.
Kurzweil said evolution moves toward God’s attributes — complexity, intelligence, creativity, love. Six of the seven are now for sale. The final entry in the scorecard.
Nike holds 45 structural-color patents to Toyota’s 20. They build the same nanoscale optics filter, then point it in opposite directions.
Kurzweil’s most mystical chapter predicted a conscious universe. What actually shipped was a patent to make a language model post on your behalf after you die.
Of 28 US patents since 2018 on engineered nitrogen-fixing crop microbes, Pivot Bio holds eight, more than anyone. The trick: deleting the gene that tells the bug to stop.
The self-replicating nanobot Kurzweil feared was never built. But his argument about it — a determined adversary defeats any centralized safeguard — just came true in a biosecurity lab, with a number attached.